Gefitinib

sensitivity

Curated

← predicts response to

sensitivity

Curated

← predicts response to

7 source records aggregated

sensitivity

Curated

Lung Non-Small Cell Carcinoma,Malignant Lung Neoplasm

← predicts response to

EGFR Mutationother

6 source records aggregated

sensitivity

Curated

← predicts response to

5 source records aggregated

sensitivity

Curated

← predicts response to

EGFR T790MSNV

4 source records aggregated

resistance

Curated

Malignant Colorectal Neoplasm,Malignant Lung Neoplasm

← predicts response to

KRAS G12CSNV

2 source records aggregated

resistance

Curated

Lung Adenocarcinoma,Malignant Lung Neoplasm

← predicts response to

KRAS G12ASNV

2 source records aggregated

resistance

Curated

← predicts response to

EGFR Amplificationamplification

2 source records aggregated

sensitivity

Curated

← predicts response to

KRAS G12SSNV

resistance

Curated

← predicts response to

KRAS G12DSNV

resistance

Curated

← predicts response to

GNAS c.393T>CSNV

resistance

Curated

← predicts response to

EGFR Expressionexpression

sensitivity

Curated

← predicts response to

EGFR L861

sensitivity

Curated

← predicts response to

EGFR G719

sensitivity

Curated

← predicts response to

KRAS Mutationother

resistance

Curated

← predicts response to

PIK3CA Mutationother

resistance

Curated

← predicts response to

EGFR G719SSNV

sensitivity

Curated

← predicts response to

PTEN Expressionexpression

sensitivity

Glioblastoma

Curated

← predicts response to

EGFR VIIIdeletion

sensitivity

Glioblastoma

Curated

← predicts response to

EGFR Overexpressionexpression

sensitivity

Curated

EGFR Y1092 PHOSPHORYLATION

← predicts response to

sensitivity

Curated

← predicts response to

KRAS G12/G13

resistance

Curated

← predicts response to

EGFR Gain-of-function

sensitivity

Curated

EGFR Rare Exon 18-21 Mutation

← predicts response to

sensitivity

Curated

← predicts response to

EGFR Wildtypeother

resistance

Curated

← predicts response to

2 source records aggregated

sensitivity

Curated

← predicts response to

ERBB2 Amplificationamplification

resistance

Curated

← predicts response to

sensitivity

Curated

← predicts response to

sensitivity

Curated

← predicts response to

KRAS G12VSNV

resistance

Curated

← predicts response to

resistance

Curated

← predicts response to

EGFR S768ISNV

sensitivity

Curated

← predicts response to

MET Amplificationamplification

resistance

Curated

← predicts response to

RAD51 Fusionfusion

sensitivity

Curated

← predicts response to

EGFR L861RSNV

sensitivity

Curated

← predicts response to

EGFR L838PSNV

sensitivity

Curated

← predicts response to

EGFR V834ISNV

sensitivity

Curated

← predicts response to

EGFR V774ASNV

sensitivity

Curated

← predicts response to

EGFR G719DSNV

sensitivity

Curated

← predicts response to

EGFR L861QSNV

sensitivity

Curated

← predicts response to

EGFR D761YSNV

resistance

Curated

← predicts response to

EGFR E746_A750deldeletion

sensitivity

Curated

← predicts response to

EGFR T790MSNV

resistance

Curated

← predicts response to

sensitivity

Curated

← predicts response to

EGFR G719ASNV

sensitivity

Curated

← predicts response to

Lung Non-Small Cell Carcinoma,Malignant Neoplasm

2 source records aggregated

sensitivity

Curated

Malignant Lung Neoplasm,Malignant Neoplasm

← predicts response to

EGFR T790MSNV

2 source records aggregated

resistance

Curated

← predicts response to

EGFR L838VSNV

resistance

Curated

← predicts response to

EGFR E746_A750deldeletion

sensitivity

Curated

← predicts response to

resistance

Curated

← predicts response to

IGF1R EXPRESSIONexpression

resistance

Curated

Malignant Colorectal Neoplasm

← predicts response to

BRAF V600ESNV

sensitivity

Curated

← predicts response to

PBK OVEREXPRESSIONexpression

resistance

Curated

← predicts response to

ERBB3 Overexpressionexpression

resistance

Curated

← predicts response to

MET Amplificationamplification

resistance

Curated

← predicts response to

EGFR G719SSNV

sensitivity

Curated

← predicts response to

sensitivity

Curated

Gefitinib targets …TARGETS1 of 1
→ targets	EGFR	—	INHIBITOR	—	1	Curated	chembl	graph →

Gefitinib targets …TARGETS1 of 1

→ targets

EGFR

—

INHIBITOR

—

Curated

Gefitinib investigated for …INVESTIGATED_FOR15 of 51show all (up to 200)
→ investigated for	Lung Non-Small Cell Carcinomasubtype	supports	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype 30 source records aggregated	supports	B	Lung Non-Small Cell Carcinoma	30	Curated	civic	graph →
→ investigated for	Lung Adenocarcinomasubtype 6 source records aggregated	supports	B	Lung Adenocarcinoma	6	Curated	civic	graph →
→ investigated for	Malignant Lung Neoplasmcancer 5 source records aggregated	supports	B	Malignant Lung Neoplasm	5	Curated	civic	graph →
→ investigated for	Glioblastomasubtype 2 source records aggregated	supports	B	Glioblastoma	2	Curated	civic	graph →
→ investigated for	Malignant Colorectal Neoplasmsubtype	supports	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	4	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype 12 source records aggregated	supports	C	Lung Non-Small Cell Carcinoma	12	Curated	civic	graph →
→ investigated for	Lung Adenocarcinomasubtype 7 source records aggregated	supports	C	Lung Adenocarcinoma	7	Curated	civic	graph →
→ investigated for	Malignant Lung Neoplasmcancer	supports	C	Malignant Lung Neoplasm	1	Curated	civic	graph →
→ investigated for	Bladder Neoplasmsubtype	unknown	3	Bladder Neoplasm	1	Curated	chembl	graph →
→ investigated for	Minimally Invasive Lung Adenocarcinomasubtype	unknown	3	Minimally Invasive Lung Adenocarcinoma	1	Curated	chembl	graph →
→ investigated for	Lung Adenocarcinomasubtype	unknown	3	Lung Adenocarcinoma	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	3	Breast Neoplasm	1	Curated	chembl	graph →

Gefitinib investigated for …INVESTIGATED_FOR15 of 51show all (up to 200)

→ investigated for

supports

Curated

→ investigated for

30 source records aggregated

supports

Curated

→ investigated for

6 source records aggregated

supports

Curated

→ investigated for

Malignant Lung Neoplasmcancer

5 source records aggregated

supports

Curated

→ investigated for

Glioblastomasubtype

2 source records aggregated

supports

Glioblastoma

Curated

Malignant Colorectal Neoplasm

→ investigated for

Malignant Colorectal Neoplasmsubtype

supports

Curated

→ investigated for

Neoplasmcancer_family

unknown

Neoplasm

Curated

→ investigated for

unknown

Curated

→ investigated for

12 source records aggregated

supports

Curated

→ investigated for

7 source records aggregated

supports

Curated

→ investigated for

Malignant Lung Neoplasmcancer

supports

Curated

→ investigated for

Bladder Neoplasmsubtype

unknown

Bladder Neoplasm

Curated

Minimally Invasive Lung Adenocarcinoma

→ investigated for

Minimally Invasive Lung Adenocarcinomasubtype

unknown

Curated

→ investigated for

unknown

Curated

→ investigated for

Breast Neoplasmcancer_family

unknown

Breast Neoplasm

Curated

Gefitinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 100show all (up to 200)
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 93 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	93	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasmcancer 32 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 20 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Head and Neck Neoplasm 18 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Head and Neck Neoplasm	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Esophageal Neoplasm 9 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Esophageal Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasmsubtype 7 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Prostate Neoplasm 7 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Adenocarcinomasubtype 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Adenocarcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Neoplasm 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ovarian Neoplasm 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ovarian Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Bladder Neoplasm 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Bladder Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Neoplasmcancer_family 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Solid Neoplasm 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Solid Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Brain Neoplasm 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Brain Neoplasm	3	Observed	clinicaltrials	graph →

Gefitinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 100show all (up to 200)

→ investigated in trials for

93 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Malignant Lung Neoplasmcancer

32 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Malignant Breast Neoplasm

→ investigated in trials for

20 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Breast Neoplasm

Observed

Malignant Head and Neck Neoplasm

→ investigated in trials for

18 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Head and Neck Neoplasm

Observed

Malignant Esophageal Neoplasm

→ investigated in trials for

9 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Esophageal Neoplasm

Observed

Malignant Colorectal Neoplasm

→ investigated in trials for

Malignant Colorectal Neoplasmsubtype

7 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Malignant Prostate Neoplasm

→ investigated in trials for

7 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Prostate Neoplasm

Observed

→ investigated in trials for

6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Lung Neoplasm

5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Lung Neoplasm

Observed

→ investigated in trials for

5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Malignant Ovarian Neoplasm

→ investigated in trials for

5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Ovarian Neoplasm

Observed

Malignant Bladder Neoplasm

→ investigated in trials for

4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Bladder Neoplasm

Observed

→ investigated in trials for

Neoplasmcancer_family

4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Neoplasm

Observed

→ investigated in trials for

Adult Solid Neoplasm

3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Adult Solid Neoplasm

Observed

→ investigated in trials for

Brain Neoplasm

3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Brain Neoplasm

Observed

Gefitinib studied in …STUDIED_INderived10 of 265show all (up to 200)
→ studied in	NCT07829926Phase 2 · not yet recruiting Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer · 265 trials list this drug (9 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03040973Phase 2 · active not recruiting Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone · 265 trials list this drug (9 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04248829Phase 3 · completed Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) · 265 trials list this drug (9 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00238628Phase 1/Phase 2 · completed A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer · 265 trials list this drug (9 active)	—	—	Malignant Lung Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03758287Phase 1/Phase 2 · completed Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative · 265 trials list this drug (9 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03122717Phase 1/Phase 2 · active not recruiting Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer · 265 trials list this drug (9 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02296125Phase 3 · completed AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer · 265 trials list this drug (9 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07477457Phase 2 · recruiting A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma · 265 trials list this drug (9 active)	—	—	Osteosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02411448Phase 3 · active not recruiting A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) · 265 trials list this drug (9 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03333343Phase 1 · active not recruiting Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC · 265 trials list this drug (9 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →

Gefitinib studied in …STUDIED_INderived10 of 265show all (up to 200)

→ studied in

NCT07829926Phase 2 · not yet recruiting

Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer · 265 trials list this drug (9 active)

—

Hepatocellular Carcinoma

Observed

→ studied in

NCT03040973Phase 2 · active not recruiting

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone · 265 trials list this drug (9 active)

—

Observed

→ studied in

NCT04248829Phase 3 · completed

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) · 265 trials list this drug (9 active)

—

Observed

→ studied in

NCT00238628Phase 1/Phase 2 · completed

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer · 265 trials list this drug (9 active)

—

Observed

→ studied in

NCT03758287Phase 1/Phase 2 · completed

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative · 265 trials list this drug (9 active)

—

Observed

→ studied in

NCT03122717Phase 1/Phase 2 · active not recruiting

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer · 265 trials list this drug (9 active)

—

Observed

→ studied in

NCT02296125Phase 3 · completed

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer · 265 trials list this drug (9 active)

—

not mapped

Observed

→ studied in

NCT07477457Phase 2 · recruiting

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma · 265 trials list this drug (9 active)

—

Osteosarcoma

Observed

→ studied in

NCT02411448Phase 3 · active not recruiting

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) · 265 trials list this drug (9 active)

—

Observed

→ studied in

NCT03333343Phase 1 · active not recruiting

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC · 265 trials list this drug (9 active)

—

not mapped

Observed